Login
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc.

kalaristx.com

What Do They Do?

Develops an investigational biologic for retinal diseases, including age-related macular degeneration, for patients with retinal conditions.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +7% (Loss)
vs −$11.9M in Q3 FY2025
  • Jul 14, 2026 Liisa Bayko appointed chief financial officer
  • Apr 8, 2026 Matthew Gall resigned as chief financial officer Brett Hagen also became principal financial officer.

From cell therapies to retinal medicine The older report described off-the-shelf T-cell therapies for viral diseases, including candidates for transplant patients; the latest report centers on an investigational treatment for retinal diseases.

Who Do They Compete With?

Competes with Roche, Novartis, Regeneron, AbbVie, Eli Lilly, Merck, Samsung Bioepis, Biogen, Coherus BioSciences, Formycon, Sandoz Group, Mylan Laboratories, Biocon Biologics, Amgen, Outlook Therapeutics, 4D Molecular Therapeutics, RegenexBio, Eyepoint Pharmaceuticals, Ocular Therapeutix, and Kodiak Sciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support